128 related articles for article (PubMed ID: 38032041)
1. Impact of non-canonical ALK fusion on the efficacy of targeted therapy in non-small cell lung cancer.
Zeng H; Wei Q; Tang Y; Zhang Y; Tan S; Huang Q; Pu X; Li Y; Tian P
Chin Med J (Engl); 2023 Nov; ():. PubMed ID: 38032041
[No Abstract] [Full Text] [Related]
2. Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer.
Kang J; Zhang XC; Chen HJ; Zhong WZ; Xu Y; Su J; Zhou Q; Tu HY; Wang Z; Xu CR; Yang XN; Chen ZH; Wu X; Zhang X; Shao Y; Wu YL; Yang JJ
Front Oncol; 2020; 10():596937. PubMed ID: 33363027
[TBL] [Abstract][Full Text] [Related]
3. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
Rosenbaum JN; Bloom R; Forys JT; Hiken J; Armstrong JR; Branson J; McNulty S; Velu PD; Pepin K; Abel H; Cottrell CE; Pfeifer JD; Kulkarni S; Govindan R; Konnick EQ; Lockwood CM; Duncavage EJ
Mod Pathol; 2018 May; 31(5):791-808. PubMed ID: 29327716
[TBL] [Abstract][Full Text] [Related]
4. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
[TBL] [Abstract][Full Text] [Related]
5. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report.
Zhu X; He Y; Wang Y; Lei Y; Su X; Liu Y; Wu S; He Z
Onco Targets Ther; 2021; 14():4915-4920. PubMed ID: 34611409
[TBL] [Abstract][Full Text] [Related]
7. [EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy].
Vašíková A
Klin Onkol; 2012; 25(6):434-9. PubMed ID: 23301645
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract][Full Text] [Related]
9. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
10. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
Ji X; Liu Y; Mei F; Li X; Zhang M; Yao B; Wu R; You J; Pei F
Sci Rep; 2021 Jul; 11(1):14031. PubMed ID: 34234236
[TBL] [Abstract][Full Text] [Related]
11. Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple
Wei Q; Zhang Y; Wang Y; Desai A; Tan S; Huang Q; Pu X; Tian P; Li Y
Transl Lung Cancer Res; 2023 Sep; 12(9):1935-1948. PubMed ID: 37854161
[TBL] [Abstract][Full Text] [Related]
12. Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion.
Qin Y; Li F; Tan Y; Duan Q; Zhang Q
Front Oncol; 2022; 12():998545. PubMed ID: 37082099
[TBL] [Abstract][Full Text] [Related]
13. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
15. Responses to
Wang R; Qin J; Fan Y; Li Z; Chen C; Su W
Onco Targets Ther; 2020; 13():4183-4187. PubMed ID: 32523354
[TBL] [Abstract][Full Text] [Related]
16. Response to crizotinib in a non-small-cell lung cancer patient harboring an
Aguado C; Gil MD; Yeste Z; Giménez-Capitán A; Teixidó C; Karachaliou N; Viteri S; Rosell R; Molina-Vila MA
Onco Targets Ther; 2018; 11():1117-1120. PubMed ID: 29535536
[TBL] [Abstract][Full Text] [Related]
17. [Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
Bai H; Han Y; Niu Y; Zhang M
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):598-604. PubMed ID: 34344501
[TBL] [Abstract][Full Text] [Related]
18. 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.
Tong Y; Zhao Z; Liu B; Bao A; Zheng H; Gu J; McGrath M; Xia Y; Tan B; Song C; Li Y
J Exp Clin Cancer Res; 2018 Mar; 37(1):68. PubMed ID: 29587818
[TBL] [Abstract][Full Text] [Related]
19. EML4-ALK fusion gene in non-small cell lung cancer.
Lei Y; Lei Y; Shi X; Wang J
Oncol Lett; 2022 Aug; 24(2):277. PubMed ID: 35928804
[TBL] [Abstract][Full Text] [Related]
20. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]